“The Israel Institute for Biological Research has received all the necessary approvals from the Ministry of Health & the Helsinki Committee for the most crucial stage in the development of a COVID -19 vaccine. Clinical trials on human participants will begin on Sunday November 1st,” the message said.
Preliminary, the trials of the vaccine will last at least six months and it will include a few stages. 80 volunteers at the age of 18 up to 55 will participate in the first stage. They should not have health issues. The vaccination will be held in the Sheba and Hadassah medical centers. Two persons will get the vaccine at the first stage. Depending on their reaction to it, the vaccine will be supplied to other volunteers.
At the second stage, 960 volunteers over the age of 18 will participate. It is expected that this stage will start in December and it will take place simultaneously in a few hospitals. At this stage, the scientists will search for the efficient dose of the vaccine and monitor its safety.
At the third stage that is expected to be held in April, the vaccine will be tested on 30,000 volunteers. It is the last stage of trials and in case of its successful completion, the vaccine might be approved for mass use.
25,000 does of vaccine prepared for trials.
As we reported, a potential Ukrainian coronavirus vaccine has already neutralized the virus in human cells. The Ukrainian coronavirus vaccine might appear in 2021, in case of positive results of clinical trials.
As of October 26, 5,426 new cases of coronavirus infection were observed in Ukraine over the last 24 hours. In total, 348,924 people have fallen ill with Covid-19 since the beginning of the pandemic in the country; 6,464 (+73) have died, and 142,537 (+1029) have managed to recover.